Want Vaccines Fast? Suspend Intellectual Property Rights
Source: New York Times
Want Vaccines Fast? Suspend Intellectual Property Rights
Otherwise, there wont be enough shots to go around, even in rich countries.
By Achal Prabhala, Arjun Jayadev and Dean Baker
Mr. Prabhala is a public health activist. Mr. Jayadev and Mr. Baker are economists.
Dec. 7, 2020, 4:01 a.m. ET
As some reports would have it, this is the beginning of the end. Three coronavirus vaccines have posted excellent results, with more expected to come.
But this is not the beginning of the end; it is only the beginning of an endless wait: There arent enough vaccines to go around in the richest countries on earth, let alone the poorest ones.
Thats why it makes little sense that the United States, Britain and the European Union, among others, are blocking a proposal at the World Trade Organization that would allow them, and the rest of the world, to get more of the vaccines and treatments we all need.
The proposal, put forward by India and South Africa in October, calls on the W.T.O. to exempt member countries from enforcing some patents, trade secrets or pharmaceutical monopolies under the organizations agreement on trade-related intellectual property rights, known as TRIPs.
It cites the exceptional circumstances created by the pandemic and argues that intellectual property protections are currently hindering or potentially hindering timely provisioning of affordable medical products; the waiver would allow W.T.O. member countries to change their laws so that companies there could produce generic versions of any coronavirus vaccines and Covid-19 treatments.
-snip-
Read more: https://www.nytimes.com/2020/12/07/opinion/covid-vaccines-patents.html
FBaggins
(26,775 posts)Fewer companies will spend what it takes to develop the next vaccine if they know that the profits will be taken away from them if theyre successful and they can just wait to knock off someone elses research.
If theres manufacturing capacity that can produce the same vaccine, then a government that wants extra supply can pay the legitimate manufacturer to subcontract the generic manufacturer to increase production.